Abstract
Gastroduodenal motility of 16 patientscomplaining of functional dyspepsia and Helicobacterpylori gastritis was recorded by means of alow-compliance manometric system with four recordingports in the stomach and four in the duodenum.Clarithromycin (CLA) 250 mg (group A: 8 patients) ornormal saline solution (group B: 8 patients) was infusedintravenously randomly and in double-blind manner 30 minafter the end of the first recorded activity front(AF) of the migrating motor complex or, in the absenceof AFs, after 200 min of recording, continuing therecording until an AF was observed during the subsequent 200 min. CLA administration was followed by atypical gastroduodenal AF in a significantly highernumber of patients than saline administration. Inaddition, the time-lag between the drug administration and the appearance of AFs was 22 min ±7.4 (mean ± SD), significantly shorter than aftersaline (109 ± 56 min) and the CLA-relatedduodenal AFs showed a duration of 7.4 min ± 1.6in group A, significantly longer than that of the spontaneous AFs (3.5min ± 1), while in group B AF duration aftersaline was not significantly different from that of thespontaneous ones. In conclusion, clarithromycin is able to stimulate cyclic interdigestivegastroduodenal motility. This prokinetic property ofclarithromycin is not unexpected because it is amacrolide like erythromycin, the prokinetic activity ofwhich is well known, and could be utilized fortherapeutic uses.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Bortolotti M, Brunelli F, Sarti, Romor A, Miglioli M: Effects of clarithromycin and amoxicillin on interdigestive gastrointestinal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. Neurogastroenterol Motil 10:61, 1998
Schwartz H, Krause R, Sahba B, Haber M, Weissfeld A, Rose P, Siepman N, Freston J: Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer occurrence: A randomized, double blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. Am J Gastroenterol 93:584–590, 1998
Lindsetmo RO, Johnsen R, Revhaugh A: Lansoprazole, amoxicillin, and clarithromycin triple therapy in vagotomized patients with dyspeptic complaints. A randomized, double blind, placebo controlled, clinical study without pretreatment diagnostic upper endoscopy. Scand J Gastroenterol 33:231–235, 1998
Annese V, Janssens J, Vantrappen G, Tack J, Peeters TL, Willemse P, Van Cutsem E: Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterology 102:823–828, 1992
Tomomasa T, Kuroume T, Arai H, Wakabayashi K, Itoh Z: Erythromycin induces migrating motor complex in human gastrointestinal tract. Dig Dis Sci 31:157–161, 1986
Peeters TL: Erythromycin and other macrolides as prokinetic agents. Gastroenterology 105:1886–1899, 1993
Bjornsson ES, Abrahamsson H: Comparison between physiologic and erytromycin-induced interdigestive motility. Scand J Gastroenterol 30:139–145, 1995
Sarna S, Soergel K, Koch T, Stone JE, Wood CM, Ryan RP, Arndorfer RC, Cavanaugh JH, Nellans HN, Lee MB: Gastrointestinal motor effects of erythromycin in humans. Gastroenterology 101:1488–1496, 1991
Talley NJ, Colin DG, Koch KL, Koch M, Nyrén O, Stanghellini V: Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 4:145–160, 1991
Peeters TL, Mattijs G, Depoortere I, Cachet T, Hoogmartens J, Vantrappen G: Erythomycin and its derivatives are motilin receptor agonists. Biomed Res Suppl 1:95, 1988
Mitty RD, Hechavarria E, Murthi D, Cave DR: Treatment of non-ulcer dyspepsia associated with Helicobacter pylori with omeprazole 1 clarithromycin: A placebo-controlled, doubleblind study. Gastroenterology 112:A221, 1997
Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain J, DeRoomuls E, Bouillon R: Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N Engl J Med 322:1028–1031, 1990
Richards RD, Davenport K, McCallum RW: The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 88:203–207, 1993
Chami TN, Schuster MM, Crowell MD, Whitehead WE: Effects of low dose erythromycin on gastrointestinal motility and symptoms in chronic intestinal pseudo-obstruction. Gastroenterology 100:A41, 1991
Di Lorenzo C, Flores AF, Tomomasa T, Hyman PE: Effect of erythromycin on antroduodenal motility in children with chronic functional gastrointestinal symptoms. Dig Dis Sci 39:1399–1404, 1994
Cucchiara S, Minella R, Scoppa A, Emiliano M, Calabrese F, Az-Zeqeh N, Rea B, Salvia G: Antroduodenal motor effects of intravenous erythromycin in children with abnormalities of gastrointestinal motility. J Pediatr Gastroenterol Nutr 24:411–418, 1997
Nellans HN, Peeters TL, Petersen AC: Stimulation of gastrointestinal motility: Clarithromycin less potent than azithromycin. In Proceedings of the 17th International Congress of Chemotherapy. Berlin 1991, pp 2286–2287
Depoortere I, Peeters TL, Mattijs G, Cachet T, Hoogmartnes J, Vantrappen G: Structure-activity relation of erythromycinrelated macrolides in inducing contractions and in displacing bound motilin in rabbit duodenum. J Gastrointest Motil 1:150–159, 1989
Rights and permissions
About this article
Cite this article
Bortolotti, M., Mari, C., Brunelli, F. et al. Effect of Intravenous Clarithromycin on Interdigestive Gastroduodenal Motility of Patients with Functional Dyspepsia and Helicobacter pylori Gastritis. Dig Dis Sci 44, 2439–2442 (1999). https://doi.org/10.1023/A:1026674719476
Issue Date:
DOI: https://doi.org/10.1023/A:1026674719476